Resources

Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk or search for MHRA Yellow Card in Google Play or Apple App Store. Adverse events should also be reported to Ipsen via email at pharmacovigilance.uk-ie@ipsen.com or phone on 01753 627777.

Cabozantinib Ipsen therapeutic indications

Cabozantinib Ipsen^® is indicated as monotherapy for advanced renal cell carcinoma:

as first-line treatment of adult patients with intermediate or poor risk,
in adults following prior vascular endothelial growth factor (VEGF)-targeted therapy

Cabozantinib Ipsen, in combination with nivolumab, is indicated for the first-line treatment of advanced renal cell carcinoma in adults.

Real World Experience

HCP experience of using cabozantinib + nivolumab to treat patients with aRCC

Video 03:18

Hear from Prof. Laurence Albiges and Prof. James Larkin sharing their experience of using Cabo+Nivo to treat patients with aRCC.

CBZ-UK-000344 | November 2024

Supporting Patients with aRCC during treatment with cabozantinib + nivolumab

Video 04:28

Hear from Prof. Laurence Albiges and Prof. James Larkin on the importance of cabo+nivo for the treatment of aRCC.

CBZ-UK-000345 | November 2024

Importance of cabozantinib + nivolumab for the treatment of aRCC

Video 05:40

Hear from Prof. Laurence Albiges and Prof. James Larkin on the importance of cabo+nivo for the treatment of aRCC.

CBZ-UK-000341 | November 2024

Adverse Event Management

IO/TKI Toxicity – How to work out which toxicities are coming from which drug

Video 17:10

Toxicity Management with combination treatment – How to work out which toxicities are coming from which drug.

CBZ-UK-000346 | November 2024

Identification and management of adverse reactions with cabozantinib in patients with advanced renal cell carcinoma

PDF / PowerPoint Deck 17 pages

A guide for healthcare professionals

CBZ-UK-000342 | November 2024

Product Resources

Median Follow-up of 55.6 months – Checkmate 9ER Data

PDF / PowerPoint Deck 3 pages

Early efficacy with sustained long-term overall survival vs sunitinib: At a median follow-up of 55.6 months (48.1 months minimum), CheckMate 9ER data for Cabozantinib + nivolumab demonstrate a 10.5-month longer mOS vs sunitinib.

CBZ-UK-000343 | November 2024